Search

Objective: The etonogestrel‐releasing implant is a long‐acting reversible contraception that is recommended by the Food and Drug Administration for 3 years and has been proven to be highly effective and convenient. Adverse effects including irregular bleeding patterns, weight gain, and acne are reported to be the main reasons for treatment discontinuation. The aim of this study is to learn the association between body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) and the incidence of side effects and adherence to treatment. Methods: This is a retrospective cohort study, conducted at a single university‐affiliated medical clinic, including all women who underwent etonogestrel‐releasing implant (Nexplanon®; New Jersey, USA, Organon USA Inc., Merck and Co) insertion between January 2019 and December 2021. Cases where abnormalities were reported during the insertion procedure or missing data were excluded from the study. Information on patients' demographic, medical history, obstetric and gynecological history, and follow‐up was collected from electronic medical files. The primary outcome was defined as the rate of implant removal in the different obesity classes. Data are presented as median and interquartile range. The study was approved by institutional review board. Results: The study population included 1318 women, of whom 466 (35%) requested early removal of the implant. Women's demographic and clinical characteristics were comparable between women who requested early removal and those with full‐length treatment. The median time for early removal was 12 (6–20) months from insertion. Irregular bleeding was the most frequent reason for early removal in both groups and was more than twice as prevalent in the early removal group (239 [51.29%] vs 193 [22%], P = 0.001). The early removal group had fewer obese women (BMI ≥30) compared with women who had full‐length treatment (163 [31.8%] vs 350 [68.2%], P = 0.03), with comparable rates of class 3 obesity women (BMI ≥40) (P = 0.68). Multi‐regression logistic analysis including age, BMI, parity and side effects found that the presence of side effects is the only independent predictor significantly associated with early implant removal (B = 1.74, P = 0.04). Conclusions: Continuation of etonogestrel‐releasing implant contraception treatment was associated with the presence of side effects that were more often reported in non‐obese women. BMI was not found to be a significant factor influencing adherence to treatment. Synopsis: Body mass index was not found to be a significant factor influencing adherence to treatment, including in morbidly obese women. [ABSTRACT FROM AUTHOR]

Background: To describe the clinical course of women with acute vaginal bleeding and a finding of uterine enhanced myometrial vascularity (EVM) with suspected retained products of conception (RPOC) on vaginal ultrasound examination. Methods: A retrospective cohort study including women with EMV and suspected RPOC attending a single tertiary medical center between April 2018 to May 2020. Women with uterine EMV were identified from medical records of the ultrasound clinics. Demographic and clinical characteristics were retrieved from women’s medical files. Results: During the study period nine women met inclusion criteria. The preceding event in seven and in two of the women was first and second trimester abortions, respectively. Of those who underwent first trimester abortion, three were surgical, two were medical and two were spontaneous. Suspected RPOC and EMV were observed by ultrasound in all cases. Six of nine women (67%) underwent uncomplicated operative hysteroscopy with removal of RPOC, and three (33%), who had severe active bleeding due to vascular malformations (arterio-venous malformation-1, pseudo-aneurysm of uterine artery-1, other vascular malformation-1) were treated with uterine artery embolization prior to operative hysteroscopy. Conclusions: Work-up of women with episodes of uterine bleeding following curettage or abortion should include color/power Doppler ultrasonography for the detection of EMV. Although in most cases EMV is a benign sonographic finding that accompany RPOC and disappear after the removal of RPOC, in women who present with acute vaginal bleeding it might hint for the presence of vascular malformations that might cause life-threatening bleeding during additional surgical interventions.

We aimed at studying isolated Fallopian tube torsion (IFTT) in a relatively large cohort of women and to evaluate different features of IFTT in comparison to a large cohort of women with non-IFTT adnexal torsion (NIAT). This was a retrospective cohort study. We included women with surgically confirmed ovarian and/or Fallopian tube torsion between March 2011 and June 2020. Fifty-four cases of IFTT were surgically confirmed during the study period and were compared to 422 surgically confirmed NIAT. The rate of controlled ovarian hyperstimulation treatments, current pregnancy, and vomiting was lower in the IFTT group compared with the NIAT group. Cervical tenderness and vaginal discharge were more common in the IFTT group. Oedematous and enlarged ovaries were less common in the IFTT group. In multivariate regression analysis, the following factors were independently associated with IFTT: (i) vaginal discharge [adjusted odds ratio (aOR) 95% CI 8.16, 1.98–33.55]; (ii) cervical motion tenderness (aOR 95% CI 2.71, 1.01–7.29); (iii) fertility treatments (aOR 95% CI 0.26, 0.70–0.77); (iv) previous abdominal surgery (aOR 95% CI 0.46, 0.22–0.96); (v) vomiting (aOR 95% CI 0.38, 0.19–0.76); and (vi) enlarged ovary (aOR 95% CI 0.34, 0.18–0.65). In conclusion, we have identified factors positively and negatively associated with IFTT in a large cohort of women with adnexal torsion. [ABSTRACT FROM AUTHOR]